Market Newsdesk

SINGAPORE, May 25, 2021 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, 1 June, 2021 at 11:30am ET. The conference will be held from 1-4 June 2021.

A live webcast of the chat will be available using this link: https://wsw.com/webcast/jeff174/asln/1851714 and in the Investor Relations section of ASLAN’s website at www.aslanpharma.com, with a replay available shortly after the event.

Media and IR contacts

Emma Thompson Spurwing Communications Tel: +65 6751 2021 Email: [email protected]	Robert Uhl Westwicke Partners Tel: +1 858 356 5932 Email: [email protected]

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first-in-class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and ASLAN003, which it plans to develop for autoimmune disease. For additional information please visit www.aslanpharma.com.

Forward looking statements

This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the “Company”). These forward-looking statements may include, but are not limited to, statements regarding the Company’s business strategy and clinical development plans; the Company’s plans to develop and commercialise ASLAN004; the safety and efficacy of ASLAN004; the Company’s plans and expected timing with respect to clinical trials and clinical trial results for ASLAN004; the potential for ASLAN004 as a differentiated treatment for atopic dermatitis; and the Company’s belief that its cash and cash equivalents will be sufficient to fund operations into 2023. The Company’s estimates, projections and other forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic on the Company’s business and the global economy; general market conditions; changes in the competitive landscape; and the Company’s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company’s US Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company’s Annual Report on Form 20-F filed with the US Securities and Exchange Commission on April 23, 2021.

All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.

VANCOUVER, British Columbia, May 25, 2021 (GLOBE NEWSWIRE) — GOLD’N FUTURES MINERAL CORP. (CSE: FUTR) (FSE: G6M), (OTC: GFTRF) (the “Company” or “Gold’n Futures”) is pleased to report it has entered into a definitive option agreement to acquire 34 mineral claims (the “Option”), covering 850 hectares (“ha”) (the “Claims”). The Claims all but surround the Company’s current Brady Gold Property and its Reid Gold Zone.

Highlights of the Option:

• The consideration to be paid pursuant to the Option is entirely common share consideration with no cash payment;
• Upon full exercise of the Option, the Company will be transferred 100% title to the Claims, subject to a 2% royalty;
• The Option expands the Brady Gold Property by approximately 9-fold to 950 ha;
• The Claims protect about 4½ km of favorable gold-related regional structure, and;
• The Claims contain gold in soil anomalies and geophysical setting for gold mineralization.

Stephen Wilkinson, President and CEO commented, “Gold’n Futures sees this Option as highly strategic and potentially very important to the ultimate advancement of our Brady gold project into production. We can confidently explore for the expansion of the Reid Gold Zone both along strike and to depth. Equally important, the Brady Gold Property gives our Company a significant beachhead in the vigorous and exciting exploration environment of Newfoundland.”

Terms of the Option

To exercise the Option, Gold’n Futures will issue, over the next three years, an aggregate of 3 million shares to the vendor. Upon completion of the share issuance, the vendor will hold a 2% Net Smelter Returns royalty. The assessment work required for 2021 to maintain the claims is $8,500 or $250/claim.

The Brady Gold Project

The Project is located 50 kilometres south of the town of Grand Falls – Windsor in central Newfoundland and is approximately 80 kilometres southwest of the New Found Gold Corp. – Queensway gold project. The Reid Gold Zone is the main area of exploration and mineralization.

The Reid Gold Zone is classified as an intrusion-hosted style of gold mineralization. Several episodes of diamond drilling totaling 30 diamond drill holes and 6,350 metres of core have defined the zone over a strike length of 300 metres, a width of 250 metres and to a vertical depth of 225 metres and the zone is reportedly open along strike and to depth.

The last reported diamond drilling on the Reid Gold Zone was in 2011 when Golden Dory Resources Corp. completed an additional 2,638.54 metres of core in eight holes (BO-11-23 to 30) and extended BO-09-16 by an additional 147.08 metres as the hole had been terminated in mineralization in 2009. The program was reportedly successful and encountered some of the best grades drilled to date including BO-11-25 which intersected 25.45 metres grading 1.48 g/t Au including 7.80 metres grading 3.62 g/t Au.

Next Steps

Gold’n Futures is planning to initiate field work exploration on the Brady Gold Project in the beginning of summer this year. Work has already commenced on compiling the historical geological, geophysical and geochemical studies with the view of targeting certain unexplained gold and arsenic, and geophysical anomalies that occur outside of the Reid Gold Zone. As soon as practical, the Company will commission a new high-definition airborne geophysical survey over the entire project claims to supplement the old government regional survey. Fieldwork will begin once the compilation and airborne survey(s) are completed to explore for altered and/or mineralized rocks in float or bedrock.

Coincident with the above, Gold’n Futures will be laying out plans for diamond drilling to infill and expand upon the historical resources of the Reid Zone, and to test any new occurrences discovered by its field programs. Drilling should be initiated upon receipt of the required permits and may be able to occur in or about September 2021.

Qualified Person

The scientific and technical content of this press release has been prepared, reviewed and approved by Mr. Walter Hanych, P. Geo., who is a Qualified Person under NI 43-101 regulations and is a director of the Company.

About Gold’n Futures Mineral Corp.

Gold’n Futures Mineral Corp. (CSE: FUTR) (FSE: G6M) (OTC: GFTRF) is a Canadian based exploration company advancing its flagship Hercules gold project located in the Hercules-Elmhurst property. The Hercules is a well-known high-grade gold Project, located 120 kilometres northeast of Thunder Bay, Ont., in the townships of Elmhurst and Rickaby, within the Thunder Bay North Mining District in the heart of the Beardmore – Geraldton gold mining camp. The property lies within an Archean greenstone belt that extends from the Longlac area in the east to Lake Nipigon in the west, a distance of about 130 kilometres. It comprises 475 contiguous claim cells (10,052 ha). To date, the work completed on the Hercules forms an extensive database including reconnaissance grab samples; channel samples; a variety of geophysical surveys; and, historical drilling totalling in the order of 537 holes – all of which is being remodeled for planning of the 2021 exploration program.

Gold’n Futures’ other gold asset is the Brady Gold Property that consists of an advanced project within a 950 ha claim group in the highly prospective Gander Zone of the central region of Newfoundland. The Brady’s Reid Gold Zone is an intrusion-hosted deposit that is only partially drill-tested and remains open on strike and at depth.

For more information, please visit our website at: www.goldnfuturesmineralcorp.com.

On behalf of the Board of Directors

For further information

Stephen Wilkinson,
President and CEO
Email: [email protected]

The Canadian Securities Exchange accepts no responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. There is no assurance the private placement, property
option, change of board or reinstatement of trading referred to above will close on the terms as stated, or at all. The Company disclaims any intention or obligation to revise or update such statements.

A document accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/b2da178a-5a51-4fd4-bc33-e8cf3a4b10ac

GARDEN CITY, N.Y., May 25, 2021 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that it will report financial results for its fourth fiscal quarter and year ended March 31, 2021 on Thursday, June 10, 2021. The Company’s management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.

Conference Call & Webcast
Thursday, June 10, 2021, 4:30 PM ET
Domestic:	877-407-0784
International:	201-689-8560
Passcode:	13720144
Webcast:	http://public.viavid.com/index.php?id=145098

About Beyond Air, Inc.
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit^®, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. LungFit^® can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit^® for clinical trials for the treatment of severe lung infections such as acute viral pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.

Forward Looking Statements

This press release contains “forward-looking statements” concerning inhaled nitric-oxide and the Company’s LungFit

^®

product, including statements with regard to potential regulatory developments, the potential impact on patients and anticipated benefits associated with its use. Forward-looking statements include statements about our expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “anticipates,” “expects,” “intends,” “impacts,” “plans,” “projects,” “believes,” “estimates,” “likely,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; our short operating history and other risks identified and described in more detail in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on our website. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.

CONTACT:
Steven Lisi, Chief Executive Officer
Beyond Air, Inc.
[email protected]

Maria Yonkoski, Head of Investor Relations
Beyond Air, Inc.
[email protected]

Corey Davis, Ph.D.
LifeSci Advisors, LLC
[email protected]
(212) 915-2577

VANCOUVER, British Columbia and IRVINE, Calif., May 25, 2021 (GLOBE NEWSWIRE) — Clean Power Capital Corp. (NEO: MOVE)(FWB: 2K6)(OTC: MOTNF) (“Clean Power” or the “Company” or “MOVE”). Clean Power Capital is pleased to provide details regarding the innovative engineering solutions PowerTap is implementing to reduce the cost of producing a kilogram of hydrogen with its Gen3 unit.

There are two general areas in which PowerTap is reducing production costs: 1) input costs; and 2) maintenance/downtime of the PowerTap Gen3 through innovative technology and engineering methods. Regarding the cost of inputs to the system, the three inputs into the system are electricity, renewable natural gas and water.

Input Cost Reduction

Electricity

PowerTap is reducing the cost of electricity in three ways – 1) incorporating electrochemical compression in system design replacing larger asymmetrical compressors that draw significantly more power; 2) reducing compression cycles to maintain 875 bar (approx. 12,700 psi) of dispensing pressure by reinventing legacy, gas-based compressed and cascaded solutions and by not implementing liquid storage solutions; and 3) implementing fuel cell technology to use excess hydrogen production to provide electrical power.

Renewable natural gas (RNG)

The design features PowerTap uses to reduce the consumption of renewable natural gas include – 1) utilizing excess CO2 to purge the system on startup in place of natural gas or nitrogen; 2) increasing the reactor’s natural gas input pressure by utilizing specialized rotary displacement pumps; and 3) recycling exhaust gas and uncaptured hydrogen from the pressure swing absorption (PSA) towers reducing the amount of RNG needed to heat the reactor’s burners.

Fresh water

The design features that reduce the consumption of fresh water include – 1) improvements to PowerTap’s water purification system and water storage solution; 2) improvements to our water expansion tanks to enable the recycling of water in the system; and 3) improvements in steam generation and injector designs.

Maintenance Cost and Downtime Reduction

In terms of reducing maintenance costs and downtime, PowerTap has implemented a number of design innovations, including – 1) incorporation of electrochemical compression versus asymmetrical compressors, which dramatically reduces maintenance costs by eliminating moving parts that require preventive maintenance and lubrication and increased corrective maintenance; 2) incorporation of a reactor tube design and catalyst composition that extends the life of the tubes and reduces periodicity of the catalyst replacement from annually to less than once every eight (8) years; 3) making design improvements that reduce the reactor internal temperatures to below 800 C, thereby extending the life of the tubes; and 4) implementation of a double redundancy design providing two independent production systems each capable of producing 625 kg of hydrogen per day, thus reducing downtime due to maintenance or system failure.

The implementation of these innovative design changes in the PowerTap Gen3 reduces the cost of goods of hydrogen production by up to 50%; reduces maintenance cost by almost 75%; and reduces down time by 50%.

“PowerTap’s center focus is to design an on-site hydrogen production and fueling system that drives the cost of hydrogen used for consumer and commercial transportation down to the gallon-of-gasoline equivalent. This is a critical goal to obtain large-scale adoption of hydrogen by commercial carriers and the public”, said Kelley Owen, PowerTap’s Chief Operating Officer.

ABOUT CLEAN POWER CAPITAL CORP.

Clean Power is an investment company that specializes in investing into private and public companies opportunistically that may be engaged in a variety of industries, with a current focus in the health and renewable energy industries. In particular, the investment mandate is focused on high return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and to seek liquidity in our investments. Clean Power’s most recent investment was in PowerTap (https://powertapfuels.com/) on October 27, 2020 (see the Company’s news release on October 28, 2020). A copy of Clean Power’s amended and restated investment policy may be found under the Company’s profile at www.sedar.com. Learn more about Clean Power by visiting our website at: https://cleanpower.capital/

Clean Power common shares are listed on the NEO Exchange. Please visit the company’s profile on the NEO Exchange website at https://www.neo.inc/en/live/security-activity/MOVE#!/market-depth.

PR Contact:
Dave Brown AMW PR
c: (917) 543-1050
[email protected]

Investor Contact:
Tyler Troup, Circadian Group IR
[email protected]

Clean Power Contact:
Raghu Kilambi
[email protected]
+1 (604) 687-2038

NEITHER THE NEO EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Notice Regarding Forward Looking Information:

This press release contains “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation.

Specifically, this news release contains forward-looking statements relating to, but not limited to: the successful installation of the PowerTap fueling units, the availability of RNG feedstock to produce blue hydrogen, PowerTap becoming eligible to earn HRI credits under the LCFS carbon credit program, the liquidity of a secondary market to sell the carbon credits, forecasts, estimates, expectations and objectives for future operations. These forward-looking statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Clean Power. Some assumptions include, without limitation, the development of hydrogen powered vehicles by vehicle makers, the adoption of hydrogen powered vehicles by the market, legislation and regulations favoring the use of hydrogen as an alternative energy source, the qualification for carbon credits, the Company’s ability to build out its planned hydrogen fueling station network, and the Company’s ability to raise sufficient funds to fund its business plan. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur or be achieved. This press release contains forward-looking statements pertaining to, among other things, the timing and ability of the Company to complete any potential investments or acquisitions, if at all, and the timing thereof. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and, in some instances, to differ materially from those anticipated by the Company and described in the forward-looking information contained in this press release.

Although the Company believes that the material factors, expectations and assumptions expressed in such forward- looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance.

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward- looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

DENVER, May 25, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today that it has received approval from Health Canada to significantly expand its cultivation capabilities at Mydecine’s Canadian Current Good Manufacturing Practice (cGMP) facility at Applied Pharmaceutical Innovation (API).

Under the new guidance from Health Canada, Mydecine will begin construction of expanded cultivation facilities in an effort to scale its supply of pharmaceutical grade psilocybin for both internal clinical research and its industry partners. The increased cultivation will also allow the Company to more efficiently and quickly study the medical utility of naturally occurring psilocybin and psilocybin-like compounds. In addition, Mydecine will be able to take a more extensive look into the diversity and undiscovered chemistry of these compounds and test their medical efficacy in treating mental health conditions like PTSD and addiction.

“Nature has produced a diversity of psilocybin producing fungi, all with their own unique chemistry and much of this diversity remains unstudied or undiscovered. The expansion of our cultivation capabilities will give us a unique lens into better understanding this incredible diversity and how it may be utilized in a therapeutic setting. It will also enhance our ability to produce pharmaceutical grade psilocybin at scale and increase our capacity to support our novel drug candidates like MYCO-001 and study its production in nature,” said Rob Roscow, Chief Science Officer at Mydecine. “Clinical use of natural extracts has seen a recent surge of commercial interest and success and expanding our capabilities to study the cultivation of a multitude of psilocybin producing mushrooms enables incredible intellectual property value and puts us on track for further discoveries of novel molecules and tryptamines.”

“Through our partnership with Mydecine, we’ve built a world class drug discovery and development platform that has positioned the Company for long-term success in its efforts to discover and better understand novel psychedelic molecules,” says API CEO Andrew MacIsaac. “Once completed, the expanded facility will have the capability to cultivate various mushrooms in quantities needed for the expanding clinical trial production needs of Mydecine as well as serve as the one of world’s broadest libraries of legally imported psilocybin producing mushrooms under a controlled substance. Tying this with our significant capacity and research infrastructure and you’ve arguably got the most well equipped companies in the space to truly move the field forward.”

About Mydecine Innovations Group
Mydecine Innovations Group™ (NEO: MYCO) (OTC: MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also successfully completed multiple acquisitions since its inception.

Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.

For more information, please contact:

Media Contacts

Anne Donohoe / Nick Opich
KCSA Strategic Communications
[email protected]
1-212-896-1265 / 1-212-896-1206

Investor Contacts

Charles Lee, Investor Relations
[email protected]
1-720-277-9879

Allison Soss / Erika Kay
KCSA Strategic Communications
[email protected]
1-212-896-1267

On behalf of the Board of Directors:

Joshua Bartch, Chief Executive Officer [email protected]

For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.

This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management’s current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.

TORONTO, May 25, 2021 (GLOBE NEWSWIRE) — Canadian Life Companies Split Corp. (“the Company”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted its notice of intention to make a Normal Course Issuer Bid (the “NCIB”) to purchase its Preferred Shares and Class A Shares through the facilities of the TSX and/or alternative Canadian trading systems. The NCIB will commence on May 27, 2021 and terminate on May 26, 2022.

Pursuant to the NCIB, the Company proposes to purchase, from time to time, if it is considered advisable, up to 1,235,290 Preferred Shares and 1,176,402 Class A Shares of the Company, representing 10% of the public float of 12,352,901 Preferred Shares and 11,764,029 Class A Shares. As of May 14, 2021, there were 12,434,901 Preferred Shares and 12,434,901 Class A Shares issued and outstanding. The Company will not purchase, in any given 30-day period, in the aggregate, more than 248,698 Preferred Shares or more than 248,698 Class A Shares, being 2% of the issued and outstanding Preferred Shares and Class A Shares as of May 14, 2021. Under the previous normal course issuer bid that commenced on May 13, 2020 and terminated on May 12, 2021, no purchases of Preferred Shares or Class A Shares were made.

The Board of Directors of the Company, on the advice of Quadravest Capital Management Inc., the Company’s investment manager, believes that such purchases are in the best interests of the Company and are a desirable use of its funds. All purchases will be made through the facilities noted above and in accordance with the rules and policies of the TSX. All Preferred Shares or Class A Shares purchased by the Company pursuant to the NCIB will be cancelled.

The Company invests in a portfolio of four publicly traded Canadian life insurance companies as follows: Great‐West Lifeco Inc., Industrial Alliance Insurance & Financial Services Inc., Manulife Financial Corporation and Sun Life Financial Inc.

Certain statements included in this news release constitute forward-looking statements, including, but not limited to, those identified by the expressions “expect”, “intend”, “will” and similar expressions to the extent they relate to the Company. The forward-looking statements are not historical facts but reflect the Company’s current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, readers are cautioned not to place undue reliance on such statements due to the inherent uncertainty therein. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statement or information whether as a result of new information, future events or other such factors which affect this information, except as required by law.

Investor Relations: 1-877-478-2372

Local: 416-304-4443

www.lifesplit.com

[email protected]

WASHINGTON, May 25, 2021 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that Morgan Magionos, a Managing Director in the firm’s Forensic and Litigation Consulting segment, has been recognized in Global Investigations Review’s Women in Investigations 2021 guide, which highlights the top 100 female practitioners in the investigations space worldwide based on nominations from readers and industry peers.

“Morgan is among an inspiring group of professionals in the Women in Investigations guide,” said Paul Ficca, Global Leader of the Forensic and Litigation Consulting segment at FTI Consulting. “She plays an integral role in helping clients who may face regulatory and compliance investigations or seek guidance on best practices to mitigate risk. I am pleased to congratulate Morgan on this well-deserved accomplishment.”

Ms. Magionos has over 15 years of forensic accounting and investigative experience. She primarily focuses on anti-corruption and anti-money laundering matters, as well as a variety of securities, investment and other financial fraud-related matters.

“It’s an honor to be named to Global Investigations Review’s Women in Investigations guide alongside so many remarkable women in the industry,” Ms. Magionos said. “I hope that the recognition of all my talented colleagues from around the world will inspire the next generation of women in investigations to commit to growth and curiosity in the field and beyond.”

About FTI Consulting

FTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political & regulatory, reputational and transactional. With more than 6,400 employees located in 29 countries, FTI Consulting professionals work closely with clients to anticipate, illuminate and overcome complex business challenges and make the most of opportunities. The Company generated $2.46 billion in revenues during fiscal year 2020. For more information, visit www.fticonsulting.com and connect with us on Twitter (@FTIConsulting), Facebook and LinkedIn.

FTI Consulting, Inc.

555 12th Street NW
Washington, DC 20004
+1.202.312.9100

Investor Contact:

Mollie Hawkes
+1.617.747.1791
[email protected] 

Media Contact:

Matthew Bashalany
+1.617.897.1545
[email protected] 

TORONTO, May 25, 2021 (GLOBE NEWSWIRE) — Canadian Banc Corp. (the “Company”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted its notice of intention to make a Normal Course Issuer Bid (the “NCIB”) to purchase its Preferred Shares and Class A Shares through the facilities of the TSX and/or alternative Canadian trading systems. The NCIB will commence on May 27, 2021 and terminate on May 26, 2022.

Pursuant to the NCIB, the Company proposes to purchase, from time to time, if it is considered advisable, up to 1,065,691 Preferred Shares and 1,058,202 Class A Shares of the Company, representing 10% of the public float of 10,656,911 Preferred Shares and 10,582,029 Class A Shares. As of May 14, 2021, there were 10,679,482 Preferred Shares and 10,679,482 Class A Shares issued and outstanding. The Company will not purchase, in any given 30-day period, in the aggregate, more than 213,589 Preferred Shares or more than 213,589 Class A Shares, being 2% of the issued and outstanding Preferred Shares and Class A Shares as of May 14, 2021. Under the previous normal course issuer bid that commenced on May 13, 2020 and terminated on May 12, 2021, no purchases of Preferred Shares or Class A Shares were made.

The Board of Directors of the Company, on the advice of Quadravest Capital Management Inc., the Company’s investment manager, believes that such purchases are in the best interests of the Company and are a desirable use of its funds. All purchases will be made through the facilities noted above and in accordance with the rules and policies of the TSX. All Preferred Shares or Class A Shares purchased by the Company pursuant to the NCIB will be cancelled.

The Company invests in a portfolio of six publicly traded Canadian Banks as follows:

Bank of Montreal	Canadian Imperial Bank of Commerce	Royal Bank of Canada
The Bank of Nova Scotia	National Bank of Canada	The Toronto-Dominion Bank

Certain statements included in this news release constitute forward-looking statements, including, but not limited to, those identified by the expressions “expect”, “intend”, “will” and similar expressions to the extent they relate to the Company. The forward-looking statements are not historical facts but reflect the Company’s current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, readers are cautioned not to place undue reliance on such statements due to the inherent uncertainty therein. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statement or information whether as a result of new information, future events or other such factors which affect this information, except as required by law.

Investor Relations: 1-877-478-2372
Local: 416-304-4443
www.canadianbanc.com
[email protected]

MONTREAL, May 25, 2021 (GLOBE NEWSWIRE) — Vision Marine Technologies, Inc. (NASDAQ: VMAR) (“Vision Marine” or the “Company”) is pleased to announce that Alan D. Gaines has been appointed to the Board of Directors and will serve as Chairman of the Board, replacing Mr. Robert Ghetti, who has resigned from Vision’s board to devote more time to other business interests.

“I am very pleased to join the board of Vision Marine Technologies and to support the highly experienced and forward thinking and ESG principled executive management team in its mandate to bring safe, eco-friendly, and low maintenance electric boating to the traditional internal combustion engine (ICE) mainstream marketplace, and in so doing disrupt the legacy boating market,” commented Mr. Gaines. “This is truly an opportunity to fast forward Vision’s footprint and to foster widespread adoption of Vision’s groundbreaking proprietary E-Motion electric outboard powertrain system with both OEMs and recreational boaters.”

“We welcome the opportunity to work with Alan and enjoy the benefits of his significant experience pertaining to capital formation and capital markets, governance and protocol, and general executive business experience,” stated Alexandre Mongeon, CEO and co-founder of Vision Marine. “His knowledge of the burgeoning electric vehicle and battery technology markets will prove invaluable to Vision’s board and its stockholders.”

Alan Gaines is a globally respected and highly experienced investment banker and entrepreneur, active within traditional renewable/sustainable cleantech, general technology, EV/CEV battery technology/chemistry, energy storage and infrastructure, as well as traditional fossil fuels. Mr. Gaines specializes in large scale capital formation, M&A, recapitalization/restructuring, and board protocol and governance. He currently serves as a Director of Auto Innovation Group, Ltd. and David Brown Automotive, Ltd., both based in the United Kingdom. With 35 years of experience as a transactional investment banker and M&A advisor, Mr. Gaines has led or participated in the raising of debt and equity totaling well over $100 billion.

Mr. Gaines previously served as founder and Chairman of Dune Energy, Inc. from its inception in May 2001 through April 2010, and serving as CEO through May 2007, when he stepped down, taking a far less active role following Dune’s acquisition of Goldking Energy Corporation, with gross proceeds totaling $540 million.

In 1983, he co-founded Gaines, Berland Inc., a full-service investment bank and brokerage specializing in global energy markets, with particular emphasis given to capital formation and M&A advisory for small and mid-cap public and private upstream and midstream companies. Gaines holds a BBA in Finance from Baruch College (CUNY), and an MBA in Finance (“With Distinction”-Valedictorian) from The Zarb School, Hofstra University Graduate School of Management.

The Board would like to thank Mr. Robert Ghetti for his guidance and leadership in helping to grow Vision Marine from a private company through its November 2020 listing on NASDAQ.

About Vision Marine Technologies

Vision Marine Technologies, Inc.’s business mandate is to change and be a contributing factor in fighting the problem of waterway pollution by disrupting the legacy boating industry with electric power, contributing to zero pollution, zero emission, and a noiseless environment.

Our flagship outboard powertrain (“E-Motion”) is the first fully electric outboard powertrain system that combines an advanced battery pack, inverter, and high efficiency motor with proprietary union assembly between the transmission and the electric motor design and extensive control software. Our E-Motion technologies used in this powertrain system are designed to improve the efficiency of the outboard powertrain and, as a result, increase range and performance.

Vision Marine continues to design, innovate, manufacture, and sell our handcrafted, high performance, environmentally friendly, electric powerboats to recreational customers. The design and technology applied to our boats results in far greater and enhanced performance, higher speeds, and longer range. Simply stated, a smoother ride and a safer and enhanced user experience than a traditional ICE motorboat.

Forward-Looking Statement

The statements contained in this press release that are not historical facts are forward-looking statements. The forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are different to predict or quantify. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory and other factors, many of which are beyond Vision’s control. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Vision’s Annual Report on Form 20-F, filed with the SEC on December 31, 2020, as such factors may be updated from time to time in Vision’s periodic filings with the SEC. Any forward-looking statement in this press release speaks only as of the date of this release. Vision undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

https://visionmarinetechnologies.com

.

Investor and Company Contact:

Bruce Nurse
Vision Marine Technologies, Inc.
(800) 871-4274
[email protected] 

Dave Gentry
RedChip Companies Inc.
800-RED-CHIP (733-2447) or 407-491-4498
[email protected] 

BEIJING, May 25, 2021 (GLOBE NEWSWIRE) — 36Kr Holdings Inc. (“36Kr” or the “Company”) (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced that it will report its first quarter 2021 unaudited financial results, on Tuesday, June 1, 2021, before the open of U.S. markets.

The Company’s management will host an earnings conference call at 8:00 AM U.S. Eastern Time on June 1, 2021 (8:00 PM Beijing/Hong Kong Time on June 1, 2021). Details for the conference call are as follows:

Event Title:	36Kr Holdings Inc. First Quarter 2021 Earnings Conference Call
Conference ID:	6166476
Registration Link:	http://apac.directeventreg.com/registration/event/6166476

All participants must use the link provided above to complete the online registration process at least 20 minutes in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in number, Direct Event passcode, and a unique registrant ID, which will be used to join the conference call.

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at http://ir.36kr.com.

A replay of the conference call will be accessible approximately two hours after the conclusion of the live call until June 8, 2021, by dialing the following telephone numbers:

United States:	+1-855-452-5696
International:	+61-2-8199-0299
Hong Kong, China:	800-963-117
Mainland China:	400-632-2162
Replay Access Code:	6166476

About 36Kr Holdings Inc.

36Kr Holdings Inc. is a prominent brand and a pioneering platform dedicated to serving New Economy participants in China with the mission of empowering New Economy participants to achieve more. The Company started its business with high-quality New Economy-focused content offerings, covering a variety of industries in China’s New Economy with diverse distribution channels. Leveraging traffic brought by high-quality content, the Company has expanded its offerings to business services, including online advertising services, enterprise value-added services and subscription services to address the evolving needs of New Economy companies and upgrading needs of traditional companies. The Company is supported by comprehensive database and strong data analytics capabilities. Through diverse service offerings and the significant brand influence, the Company is well-positioned to continuously capture the high growth potentials of China’s New Economy.

For more information, please visit: http://ir.36kr.com.

For investor and media inquiries, please contact:

In China:

36Kr Holdings Inc.
Investor Relations
Tel: +86 (10) 5825-4188
E-mail: [email protected]  

The Piacente Group, Inc.
Jenny Cai
Tel: +86 (10) 6508-0677
E-mail: [email protected]  

In the United States:

The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: [email protected]